Skip to main content
. 2022 Mar 15;43(10):2636–2650. doi: 10.1038/s41401-022-00889-4

Fig. 8. Sotagliflozin enhances neovascularization in diabetic HLI mice.

Fig. 8

a, b Blood perfusion in the ischemic hindlimbs of diabetic HLI mice administered intramuscularly with sotagliflozin at indicated times. Representative images (a) and quantification data of blood perfusion ratio were shown (b; n = 7). c Morphological assessment of ischemic hindlimb in diabetic HLI mice intramuscularly injected with sotagliflozin at indicated time points (n = 7). d, e Immunofluorescence against PECAM-1 (green) and α-SMA (red) in ischemic hindlimbs tissue of diabetic HLI mice intramuscularly injected with sotagliflozin at day 21 after surgery. Representative images (d; scale bars: 50 μm) and quantification results (e; n = 6) were shown. f Immunohistochemical staining of HIF-1α in ischemic hindlimbs tissue of diabetic HLI mice intramuscularly injected with sotagliflozin at day 21 after surgery. Representative images (scale bars: 50 μm) were shown. g, h Protein expression levels of angiogenic factors in the ischemic hindlimbs of diabetic HLI mice intramuscularly injected with sotagliflozin, as examined using Western blotting. Representative images (g) and quantification results (h) were shown. β-Actin was used as Western blotting loading control. Quantitative data were presented as mean ± SD (n = 3, unless further indicated). Con mice were administered with 10% DMSO, Sota mice were administered with sotagliflozin (10 mg/kg body weight), NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001.